CN107029074A - A kind of pharmaceutical composition and preparation method and purposes for treating fatty liver - Google Patents
A kind of pharmaceutical composition and preparation method and purposes for treating fatty liver Download PDFInfo
- Publication number
- CN107029074A CN107029074A CN201710423166.8A CN201710423166A CN107029074A CN 107029074 A CN107029074 A CN 107029074A CN 201710423166 A CN201710423166 A CN 201710423166A CN 107029074 A CN107029074 A CN 107029074A
- Authority
- CN
- China
- Prior art keywords
- parts
- pharmaceutical composition
- preparation
- medicine
- purposes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
- A61K36/296—Epimedium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/884—Alismataceae (Water-plantain family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
- A61K36/8888—Pinellia
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a kind of pharmaceutical composition for treating fatty liver, it is the preparation that the raw material matched by following weight is prepared from：10 12.5 parts of barrenwort, 15 20 parts of the Radix Astragali, 5 7.5 parts of Poria cocos, 5 7.5 parts of the bighead atractylodes rhizome, 7.5 10 parts of rhizoma alismatis, 7.5 10 parts of dried orange peel, 7.5 10 parts of the tuber of pinellia, 15 20 parts of raw hawthorn, 15 20 parts of the red sage root.Present invention also offers the preparation method of the pharmaceutical composition and purposes.Pharmaceutical composition of the present invention, compatibility is precise and appropriate, and each flavour of a drug complement each other, and for treating, fatty liver is evident in efficacy, and new selection is provided for clinical treatment.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition for treating fatty liver and its production and use, belong to the field of Chinese medicines.
Background technology
Non-alcohol fatty liver (Nonalcoholic fatty liver disease, NAFLD) is a kind of and pancreas
Insulin resistance (insulin resistance, IR) and the closely related metabolic stress hepar damnification of inheritance susceptible, its pathology
Learn and change similar with AML (Alcoholic fatty liver disease, ALD), but patient is without excessive drinking history,
Spectrum of disease includes non-alcoholic simple fatty liver (Nonalcoholic fatty liver, NAFL), NASH
Scorching (Nonalcoholic steatohepatitis, NASH) and its related liver cirrhosis and hepatocellular carcinoma (Hepatocellular
Carcinoma, HCC).With the improvement of living standards, the change of life style and dietary structure, the NAFLD incidences of disease are constantly carried
Rise, be increasingly becoming one of global important public health problem.
Survey data shows, is chronic liver disease most commonly encountered diseases because overall prevalence rate is left 25% in western countries NAFLD
The right side, ratio then increases to 70% in obese people and diabetes B patient.It is also pessimistic in the epidemiology survey of China,
The NAFLD incidences of disease are up to 20.7%, and its illness rate, the incidence of disease are constantly increased among crowd in recent years, and age of onset
There is the trend that becomes younger.At present, in the prevalence of Chinese fat and metabolic syndrome, NAFLD instead of chronic hepatitis B
As the first big chronic hepatic diseases.For NAFLD harm, it is similar to AML, viral liver disease, Ke Yitong
Inflammation is crossed, and then occurs hepatic sclerosis, liver cancer, or even liver failure.But comparatively, NAFLD generations hepatic sclerosis, liver are thin
The probability of born of the same parents' cancer is relatively low；In addition, from fat hepatitis to hepatic sclerosis, for such a process of liver cancer, NAFLD is than virus
Time required for property hepatitis is long.But in European and American developed countries, particularly for the U.S., liver transplant caused by NAFLD
Second has been come, chronic hepatitis C is only second to；And among the HCC causes of disease, NAFLD growth rates rise rapidly, at present
Seem to have instead of AML, as second largest reason.Therefore for NAFLD pathogenesis and grinding for drug therapy
Study carefully and have very important significance.
Specific means and medicine are there is no currently for NAFLD treatments.Treatment mainly includes Primary Care and medicine is controlled
Treat.Primary Care is the mode of making the life better, and is such as kept on a diet, and strengthens motion exercise to lose weight.Drug therapy includes
Five major classes：(1) insulin resistance medicine is improved：Common drug is insulin sensitizer, including double by representative of melbine
Guanidine medicine and using Rosiglitazone, Pioglitazone as representative thiazolidinediones；(2) lipid-lowering medicine：With fibrates and Statins
For represent, Statins be mainly used in drop TC and LDL-C, fibrates be mainly used in TG raise based on hyperlipidemia；(3) liver protection
Anti-inflammatory agent：Glycyrrhizin plays its powerful liver protection antiinflammatory action by the effect of its steroids, and Polyene Phosphatidylcholine capsule leads to
Combined after specifically with liver plasma membrane, stable, protection, reparation liver plasma membrane, promotion liver cell regeneration, such as urso,
Worked by preventing Apoptosis and suppressing inflammatory reaction；(4) antioxidant：Such as vitamin E, pass through anti-lipid peroxidation
Reduced with the antioxidant level of free radical, reach the process for delaying NAFLD to proceed to NASH；(5) probiotics：Enteron aisle is thin
Bacterium undue growth can produce endogenous alcohol, release endotoxin, stimulate inflammatory cytokine to produce the damage for participating in NAFLD.But
It is that these medicines have certain side effect：As thiazolidinediones and fat-reducing medicament have certain hepatic injury effect, and lipid-loweringing
Medicine is discontinued and can rebounded, and not can effectively improve liver inner lipid deposition；Biguanides has risk for causing lactic acidosis etc..
So at present still without a kind of granted treatment for NAFLD of medicine.
It is simple to rely on liver protection anti-inflammatory drug, lipid-lowering medicine, the effect for improving insulin resistance drug therapy NAFLD and pay no attention to
Think, and curative effect is single there is different toxicity and adverse reaction.Compared with doctor trained in Western medicine, traditional Chinese medicine has multipath, multi-angle, many
The characteristics of level, Mutiple Targets integrate pharmacological action, treatment by Chinese herbs NAFLD has obvious advantage, essentially consists in Chinese medicine and is easy to specify
Individualized treatment scheme, it is more more efficient than simple lipid-loweringing, liver protecting therapy scheme.Available for treatment NAFLD Chinese medicine compound prescription or
Person's unit Chinese medicine species is more, and safe coefficient is high, and curative effect stablizes lasting in terms of NAFLD is prevented and treated, and toxic side effect is small, and price is low
It is honest and clean.
The Chinese medicine report for the treatment of fatty liver is more at present, such as：Zhong Yanchun, Chinese medicine fatty liver progress, Liaoning traditional Chinese medical science
Medicine college journal, 2 months the 2nd phases of volume 10 in 2008, is treated according to the etiology and pathogenesis of patients with fatty liver by Chinese medicine, medicine typing, open
Also there are many problems in a variety of different prescriptions, current this disease of Chinese medicine, such as tcm diagnosis, differentiation of symptoms and signs for classification of syndrome, judge mark
Accurate and curative effect determinate standard disunity, objective indicator is indefinite, and late result observation is few, lacks large sample, polycentric strict
Randomized control study, is studied seldom in terms of therapy mechanism and pharmacological action link, it is necessary to constantly improve and determine unified fat
Differentiation of symptoms and signs for classification of syndrome, diagnostic criteria and the curative effect determinate standard and quantization objective indicator of liver treatment, are carried out to the traditional Chinese medicine mechanism of action
The research of science extensively, for clinical treatment, this disease provides reliable and effective evidence.Number of patent application：
CN201310305337.9, denomination of invention：It is a kind of to treat Chinese medicine composition of fatty liver and preparation method thereof, the disclosure of the invention
It is a kind of to treat Chinese medicine composition of fatty liver and preparation method thereof, it is made up of the following raw material medicine by certain weight proportion：Malt,
Poria cocos, the bighead atractylodes rhizome, the fleece-flower root, rhizoma alismatis, sealwort, the Radix Astragali, the red sage root, giant knotweed, lotus leaf, the radix paeoniae rubrathe, rhizoma atractylodis, parasitism, Morinda officinalis, Fructus meliae toosendan,
Radix Angelicae Sinensis, radix bupleuri, cassia seed, rhizoma pinellinae praeparata, the coptis, moutan bark, rascal, the dried immature fruit of citron orange, Radix Codonopsis, dried orange peel, root tuber of aromatic turmeric, radix glycyrrhizae, Rhizoma Sparganii, curcuma zedoary,
The prescription has dispersing stagnated hepatoqi, promoting blood circulation and removing blood stasis, promoting digestion and removing indigestion function, and prescription raw material dosage is more disclosed in this application, is unfavorable for
Clinical practice and industrialized production.
The content of the invention
It is an object of the invention to provide a kind of Traditional Chinese medicine composition of new treatment fatty liver.Another mesh of the present invention
The preparation method and use that there is provided the pharmaceutical composition.
The pharmaceutical composition of present invention treatment fatty liver, it is the preparation that the raw material matched by following weight is prepared from：
10-12.5 parts of barrenwort, 15-20 parts of the Radix Astragali, 5-7.5 parts of Poria cocos, 5-7.5 parts of the bighead atractylodes rhizome, 7.5-10 parts of rhizoma alismatis, dried orange peel
7.5-10 parts, 7.5-10 parts of the tuber of pinellia, 15-20 parts of raw hawthorn, 15-20 parts of the red sage root.
Preferably, it is the preparation that the raw material matched by following weight is prepared from：
10 parts of barrenwort, 15 parts of the Radix Astragali, 7.5 parts of Poria cocos, 7.5 parts of the bighead atractylodes rhizome, 10 parts of rhizoma alismatis, 10 parts of dried orange peel, 7.5 parts of the tuber of pinellia,
15 parts of raw hawthorn, 15 parts of the red sage root.
Wherein, described pharmaceutical composition be by the bulk drug primary medicinal powder or water or extractive with organic solvent for live
Property composition, adds the preparation that pharmaceutically acceptable auxiliary material or complementary composition are prepared from.
Preferably, the preparation is oral formulations.It is further preferred that it is particle that the oral formulations, which are described preparation,
Agent, tablet, capsule, oral liquid.
Present invention also offers the preparation method of foregoing pharmaceutical composition, it includes following operating procedure：
(1) raw material of each weight proportion is weighed；
(2) beat powder or add water or organic solvent extraction, add pharmaceutically acceptable auxiliary material or be prepared by complementary composition
Preparation.
Present invention also offers purposes of the foregoing pharmaceutical composition in the medicine for preparing treatment fatty liver.Wherein, it is described
Medicine be treat NASH medicine.
Present invention also offers purposes of the described pharmaceutical composition in the medicine for preparing prevention liver fibrosis.
The use during there is warming Yang, enlivening spleen, the medicine of clearing damp resolving sputum is being prepared present invention also offers foregoing pharmaceutical composition
On the way.
The fat deficiency of yang, type of stagnation of phlegm-damp NASH are clinical Common Syndromes types, and morbidity crowd is wide, pathogeny radix
Greatly, serious to threaten the people's healthy, tcm clinical practice still lacks the reliable medicine directly against the card type.According to the card
The etiology and pathogenesis feature of type, proposes the theory of pathogenesis of " damp-retention due to hypofunction of the spleen, phlegm and blood stasis ", with " warming Yang, enlivening spleen, the Pulvis Expectorans stasis of blood " for base
This rules for the treatment of.Radix Astragali invigoration spleen qi helps spleen sending up the lucid YANG in medicine material prescription of the present invention；Barrenwort temperature yang transforming qi, tonifying kidney and strengthening yang is dispelled
Wind dehumidifies；The bighead atractylodes rhizome, Poria cocos, in the sweet temperature compensation of the bighead atractylodes rhizome, tonifying spleen eliminating dampness, benefiting qi for promoting production of blood, and in disappear it is stagnant；Poria cocos it is sweet it is light ooze profit, invigorating the spleen is mended
In, clearing damp and promoting diuresis, two medicines 5 are used, and one strong one oozes, and water is wet, there is an outlet, therefore spleen can be good for, wet remove；Coix seed clearing damp and promoting diuresis, is good for
Spleen；Rhizoma alismatis clearing damp and promoting diuresis；Dried orange peel, the tuber of pinellia, dried orange peel regulating qi-flowing for strengthening spleen, and stomach resolving sputum, the tuber of pinellia is eliminating dampness and eliminating phlegm, and dissolving lump and resolving mass, invigorating the spleen stops
Vomit, the two enters the spleen channel, two medicines are referred and synthesized, mutually promoted, thus spleen can be good for, it is wet go, phlegm from disappearing, mechanism of qi is unobstructed；Raw hawthorn nature and flavor
Acid is sweet, and it is stagnant to be longer than disperse accumulationsization, cures mainly meat stagnation, is longer than scattered stasis analgesic；Red sage root promoting blood circulation.Head replenishes qi to invigorate the spleen again, temperature
Warm spleen sun, and with the Pulvis Expectorans stasis of blood.
Pharmaceutical composition of the present invention, compatibility is precise and appropriate, and each flavour of a drug complement each other, and the curative effect to fatty liver is clear and definite, toxic side effect
It is small, provide a kind of new selection for clinical treatment fatty liver.
Obviously, according to the above of the present invention, according to the ordinary technical knowledge and customary means of this area, do not departing from
Under the premise of the above-mentioned basic fundamental thought of the present invention, the modification of other diversified forms can also be made, replaces or changes.
The embodiment of form, remakes further specifically to the above of the invention by the following examples
It is bright.But the scope that this should not be interpreted as to above-mentioned theme of the invention is only limitted to following example.It is all to be based on the above of the present invention
The technology realized belongs to the scope of the present invention.
Brief description of the drawings
Fig. 1 oil red O stain results.A. Chinese medicine high dose group, B. middle dose groups, C. low dose groups, D. positive drug groups, E.
Model group, F. blank groups
Fig. 2 .qPCR results.A.TLR4, B.NF- κ B, C.TGF- β 1, D.Smad3
Embodiment
Embodiment 1：The preparation of medicine of the present invention
Take barrenwort 10g, Radix Astragali 15g, Poria cocos 7.5g, bighead atractylodes rhizome 7.5g, rhizoma alismatis 10g, dried orange peel 10g, tuber of pinellia 7.5g, raw hawthorn
15g, red sage root 15g, add 10 times of amount water, and soaked overnight supplies water absorption, decoct 3 times, 1 hour every time, filter, merging filtrate,
Produce.
Usage and consumption：Orally, one day it is one, 3 times a day.
Embodiment 2：The preparation of medicinal granule of the present invention
Take barrenwort 10g, Radix Astragali 15g, Poria cocos 7.5g, bighead atractylodes rhizome 7.5g, rhizoma alismatis 10g, dried orange peel 10g, tuber of pinellia 7.5g, raw hawthorn
15g, red sage root 15g, add 10 times of amount water, and soaked overnight supplies water absorption, decoct 3 times, 1 hour every time, filter, merging filtrate,
Filtrate decompression is condensed into the medicinal extract that relative density is 1.25 (60 DEG C)；Medicinal extract is mixed with 3 times of amount dextrin, prepares softwood, swing
Granulator is pelletized, and 60 DEG C of dry 0.5h, whole grain screens out fine particle, is packed, is produced.
Embodiment 3：The preparation of medicinal tablet of the present invention
Take barrenwort 10g, Radix Astragali 15g, Poria cocos 7.5g, bighead atractylodes rhizome 7.5g, rhizoma alismatis 10g, dried orange peel 10g, tuber of pinellia 7.5g, raw hawthorn
15g, red sage root 15g, add 10 times of amount water, and soaked overnight supplies water absorption, decoct 3 times, 1 hour every time, filter, merging filtrate,
Filtrate decompression is condensed into the medicinal extract that relative density is 1.25 (60 DEG C)；Medicinal extract is mixed with 3 times of amount dextrin, prepares softwood, swing
Granulator is pelletized, 60 DEG C of dry 0.5h, single-punch tablet press tabletting, is prepared the tablet that size is 0.3g, is produced.
Beneficial effects of the present invention are proved below by way of specific experiment.
Cell pharmacodynamics and its Mechanism Study of the medicine Contained Serum of the present invention of test example 1 to non-alcohol fatty liver
1. experiment material
1.1 instruments and reagent
CO2 incubators (Nuare companies of the U.S.), superclean bench (Jinan is tall and erect difficult to understand), inverted microscope (Japanese Olympus
Company), table-type low-speed centrifuge (Thermo companies of the U.S.), ultrasonic cell disintegration instrument (Nanjing stars Science and Technology Ltd.), enzyme
Mark instrument (Thermo companies of the U.S.), Thermo companies of the U.S. (Zhejiang Saden), the real-time fluorescence quantitative PCR instrument (ABI of ABI 7500
7500)。
DMEM culture mediums (Gibco companies of the U.S.), hyclone (Hangzhou Sijiqing Biological Engineering Material Co., Ltd.), pancreas
Enzyme (Gibco companies of the U.S.), oleic acid (MP companies of the U.S.), oil red O (SIGMA companies of the U.S.), triglycerides (TG) determines reagent
Box (bio tech ltd is built up in Nanjing), M-MLV Frist Stand cDNA Synthesis Kit (OMEGA companies),
SYBR Green PCR Master Mix kits (Applied biosystems companies), Tirzol (AMBION companies), liver
JEG-3 HepG2 (derives from Hospital Affiliated To Chengdu Traditional Chinese Medicine Univ central laboratory cell bank).Polyene Phosphatidylcholine glue
Capsule (228mg*24, Sai Nuofei pharmaceutical Co. Ltds), is purchased from Hospital Affiliated To Chengdu Traditional Chinese Medicine Univ.
1.2 experimental animal
Cleaning grade male Wistar rat 70,200 ± 20g of body weight is provided, animal by Jianyang of Sichuan up to large biotech firm
Quality certification number：SCXK (river) 2008-011.
2. experimental method
The preparation of 2.1 medicine Contained Serums of the present invention
Male Wistar rat 70 is only randomly divided into 5 groups, i.e. Chinese medicine high dose, Chinese medicine middle dosage, Chinese medicine low dosage, the positive
Control group (Polyene Phosphatidylcholine Capsules group), blank group, every group 14.According to people and rat body surface area Commutation Law, give
High, medium and low dosage group difference gavage 18.8g/kg, 9.4g/kg, 4.7g/kg of medicine (prepared by embodiment 1) of the present invention is positive right
According to a group 122.14mg/kg, daily dose gavage in two times is spaced 8h, and blank group gives isometric distilled water, continuous 7 days.Last
After administration 1 hour, rat aorta takes blood, stands, and centrifugation obtains Contained Serum.
2.2 HepG2 cell culture and packet
By HepG2 cells with 1 × 105The cell that individual/hole is inoculated in 12 well culture plates into exponential phase is tested.
Cell length is treated to 70-80%, original nutrient solution is discarded, plus appropriate PBS is washed twice.
6 groups of experiment point：
Blank group：Add ordinary culture medium culture；
Model group：Add the culture medium of the oleic acid containing 0.25mM.
Positive drug group：The positive drug Contained Serum of addition 10% in the nutrient solution of the oleic acid containing 0.25mM.
The high, medium and low dosage group of Chinese medicine：The high, medium and low dosage of Chinese medicine of addition 10% in the nutrient solution of the oleic acid containing 0.25mM
Contained Serum.
2.3 oil red O stain
Empirically it is grouped and culture 24h is carried out to cell, inhales and abandon culture medium, PBS 3 times, 4% paraformaldehyde is fixed
30min, PBS 2 times adds 60% isopropanol and synchronizes liquid, oil red O working solutions lucifuge is incubated 30min, and 60% isopropanol enters
Row color separation about 30s is to background colour completely without ddH2O washes 3min, and haematoxylin redyes 3-5min, ddH2O is washed 3 times, each 2min, ddH2O
Fluid-tight, in observing cell fat drips situation under inverted microscope, takes the different visuals field of different multiples to take pictures.
The measure of 2.4 intracellular TG/ protein contents
Empirically it is grouped and cell is handled, culture medium is abandoned in suction, PBS 3 times adds 200 μ L0.25% pancreatin and disappeared
Change, sop up pancreatin, add the appropriate DMEM containing 10%FBS and cell is resuspended, centrifugation adds 1ml cell pyrolysis liquids in ultrasonic cell
Crushed under broken instrument, be placed in and be incubated 20min on ice, centrifuging and taking supernatant.Determine thin according to BCA protein quantifications kit specification
Intracellular protein content, intracellular TG contents are determined according to triglyceride reagent box specification.
Calculated according to formula：Intracellular triglyceride content (mmol/gprot)=(sample OD values-blank OD values)/(mark
Quasi- OD values-blank OD values) × calibration object concentration (2.26mmol/L) ÷ samples to be tested protein concentration (gprot/L)
Target gene (TLR4, NF- κ B, TGF-β 1 and Smad3) is in mRNA level in-site in 2.5 qPCR methods detection HepG2 cells
Expression
Each group cell culture fluid in orifice plate is collected, collected after centrifugation supernatant extracts RNA, strictly using trizol reagents
According to Reverse Transcriptase kit specification and SYBRR Green PCR Master Mix kit specifications detection cell in TLR4,
The expression quantity of NF- κ B, TGF-β 1, Smad3 in mRNA level in-site.
3. statistical procedures
Data are handled using the softwares of SPSS 21.0, experimental result is with means standard deviationRepresent, number
According to meeting normal distribution, homogeneity of variance, therefore compare the mean of blank group and model group, the tables of p ＜ 0.05 using independent samples t test
It is shown with statistical significance.
4. experimental result
4.1 each group cell drugs intervene HepG2 cell oil red O stain results after 24h
Blank group cell edges are clear, and endochylema enriches, and nuclear membrane is complete, and nucleus is dyed to blueness, intracellular to have no obvious
Red fat drips；The intracellular red fat drips for occurring much differing in size of model group, fat becomes mounting portion and even merges in blocks；Sun
Property medicine group, nucleus is dyed to blueness, the different degrees of red fat drips particle of intracellular appearance in the high, medium and low dosage group of Chinese medicine.
Compared with model group, the low middle high dose of Chinese medicine and the intracellular red fat drips particle of positive drug group are reduced.
4.2 intracellular TG/ protein contents results
Compared with blank group, model group cell TG contents are significantly raised, p ＜ 0.01, with conspicuousness statistical significance.
Compared with model group, TG contents decrease in Chinese medicine senior middle school low dose group cell, p ＜ 0.05, with statistics
Meaning, and TG contents are substantially reduced in positive drug group cell, p ＜ 0.01, with conspicuousness statistical significance.
The TG/ protein contents of table 1
Note：Compared * p ＜ 0.05, * * p ＜ 0.01 with blank group；Compared with model group#P ＜ 0.05,##P ＜ 0.01
Target gene (TLR4, NF- κ B, TGF-β 1 and Smad3) is in mRNA level in-site in 4.3 qPCR methods detection HepG2 cells
Expression of results
Compared with blank group, the expression quantity of model group target gene TLR4, NF- κ B, TGF-β 1, Smad3 in mRNA level in-site
Substantially up-regulation.
Compared with model group, Chinese medicine high dose group, middle dose group, low dose group, positive drug group TLR4, NF- κ B, TGF-β
1st, Smad3 is substantially lowered in the expression quantity of mRNA level in-site.
5. conclusion
After Contained Serum processing NAFLD cells 24 hours, oil red O stain, TG/ protein contents, qPCR measurement results are shown：
Compared with model group, Chinese medicine group can reduce the TG contents in NAFLD cells, it may be possible to by lower target gene TLR4,
NF- κ B play a role to treat NAFLD in the expression quantity of mRNA level in-site.And Chinese medicine group simultaneously can lower TGF-β 1 in cell,
Smad3 mrna expression amount, reaches the effect of prevention liver fibrosis.
Pharmaceutical composition of the present invention, compatibility is precise and appropriate, and each flavour of a drug complement each other, and the curative effect to fatty liver is clear and definite, and can be used for
Prevent liver fibrosis, toxic side effect is small, and a kind of new selection is provided for clinical treatment fatty liver.
Claims (10)
1. a kind of pharmaceutical composition, it is characterised in that：It is the preparation that the raw material matched by following weight is prepared from：
10-12.5 parts of barrenwort, 15-20 parts of the Radix Astragali, 5-7.5 parts of Poria cocos, 5-7.5 parts of the bighead atractylodes rhizome, 7.5-10 parts of rhizoma alismatis, dried orange peel 7.5-
10 parts, 7.5-10 parts of the tuber of pinellia, 15-20 parts of raw hawthorn, 15-20 parts of the red sage root.
2. pharmaceutical composition according to claim 1, it is characterised in that：It is the raw material matched by following weight prepare and
Into preparation：
10 parts of barrenwort, 15 parts of the Radix Astragali, 7.5 parts of Poria cocos, 7.5 parts of the bighead atractylodes rhizome, 10 parts of rhizoma alismatis, 10 parts of dried orange peel, 7.5 parts of the tuber of pinellia, raw mountain
15 parts of short, bristly hair or beard, 15 parts of the red sage root.
3. pharmaceutical composition according to claim 1 or 2, it is characterised in that：It is the primary medicinal powder by the bulk drug,
Or water or extractive with organic solvent are active component, add pharmaceutically acceptable auxiliary material or complementary composition is prepared from
Preparation.
4. pharmaceutical composition according to claim 3, it is characterised in that：The preparation is oral formulations.
5. pharmaceutical composition according to claim 4, it is characterised in that：The oral formulations are granule, tablet, capsule
Agent, oral liquid.
6. a kind of preparation method for preparing Claims 1 to 5 any one described pharmaceutical composition, it is characterised in that：It includes
Following operating procedure：
(1) raw material of each weight proportion is weighed；
(2) beat powder or add water or organic solvent extraction, add pharmaceutically acceptable auxiliary material or complementary composition is prepared from
Preparation.
7. purposes of the pharmaceutical composition in the medicine for preparing treatment fatty liver described in Claims 1 to 5 any one.
8. purposes according to claim 7, it is characterised in that：Described medicine is the medicine for treating NASH
Thing.
9. purposes of the pharmaceutical composition in the medicine for preparing prevention liver fibrosis described in Claims 1 to 5 any one.
10. Claims 1 to 5 any one described pharmaceutical composition is in preparing with warming Yang, enlivening spleen, the medicine of clearing damp resolving sputum
Purposes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710423166.8A CN107029074A (en) | 2017-06-07 | 2017-06-07 | A kind of pharmaceutical composition and preparation method and purposes for treating fatty liver |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710423166.8A CN107029074A (en) | 2017-06-07 | 2017-06-07 | A kind of pharmaceutical composition and preparation method and purposes for treating fatty liver |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107029074A true CN107029074A (en) | 2017-08-11 |
Family
ID=59541843
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710423166.8A Pending CN107029074A (en) | 2017-06-07 | 2017-06-07 | A kind of pharmaceutical composition and preparation method and purposes for treating fatty liver |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107029074A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111358902A (en) * | 2020-04-15 | 2020-07-03 | 李经纬 | Traditional Chinese medicine ointment formula applied to fatty liver and processing method thereof |
| CN114796366A (en) * | 2022-03-30 | 2022-07-29 | 广州中医药大学第一附属医院 | Traditional Chinese medicine composition and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104383183A (en) * | 2014-12-10 | 2015-03-04 | 崔合芳 | Medicinal composition for treating non-alcoholic fatty liver |
| KR20150105616A (en) * | 2014-03-07 | 2015-09-17 | 동의대학교 산학협력단 | Composition comprising herbal extract for preventing or treating fatty liver disease |
-
2017
- 2017-06-07 CN CN201710423166.8A patent/CN107029074A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20150105616A (en) * | 2014-03-07 | 2015-09-17 | 동의대학교 산학협력단 | Composition comprising herbal extract for preventing or treating fatty liver disease |
| CN104383183A (en) * | 2014-12-10 | 2015-03-04 | 崔合芳 | Medicinal composition for treating non-alcoholic fatty liver |
Non-Patent Citations (3)
| Title |
|---|
| 华何与等: "《读经典学名方系列 肝胆病名方》", 30 September 2013, 中国医药科技出版社 * |
| 张莉等: "中西医结合治疗非酒精性脂肪性肝硬化效果评价", 《中医药导报》 * |
| 李晓斐: "《临床常见肝病诊疗进展》", 31 May 2015, 西安交通大学出版社 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111358902A (en) * | 2020-04-15 | 2020-07-03 | 李经纬 | Traditional Chinese medicine ointment formula applied to fatty liver and processing method thereof |
| CN114796366A (en) * | 2022-03-30 | 2022-07-29 | 广州中医药大学第一附属医院 | Traditional Chinese medicine composition and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113616747B (en) | Traditional Chinese medicine composition for healing infectious diseases and application thereof | |
| MXPA03003446A (en) | Novel medicinal herbal composition for treating liver diseases and hiv. | |
| CN102139084B (en) | Chinese medicinal composition for treating fatty liver and preparation method and application thereof | |
| CN112972547A (en) | Traditional Chinese medicine composition for treating qi-blood deficiency syndrome and preparation method and application thereof | |
| CN1299742C (en) | Medicine for treating diabetes, and its prepn. method | |
| US11160842B2 (en) | Drug or health care product preventing or treating liver and kidney damage-related diseases and use thereof | |
| CN102488798B (en) | Medicine for treating non-alcoholic fatty liver | |
| CN111991484A (en) | A pharmaceutical composition for treating respiratory diseases in winter | |
| CN103919878A (en) | Medicine for treating fatty liver and hyperlipidaemia and preparation process thereof | |
| CN107029074A (en) | A kind of pharmaceutical composition and preparation method and purposes for treating fatty liver | |
| CN101375988B (en) | Anti-inflammation formulation for treating acute prostatitis and preparation method thereof | |
| CN112826889A (en) | Traditional Chinese medicine composition for treating non-alcoholic fatty liver disease | |
| CN111803600A (en) | Traditional Chinese medicine composition for preventing and treating non-alcoholic fatty liver disease and preparation method | |
| CN111729054A (en) | Dampness-resolving toxin-vanquishing traditional Chinese medicine composition, traditional Chinese medicine preparation, preparation method and application thereof | |
| CN104042895A (en) | Traditional Chinese medicine composition for treating systemic lupus erythematosus and use thereof | |
| CN105327115B (en) | A kind of prevention and treatment type II diabetes Phellinus is logical to rush down formula and preparation process | |
| CN103877323B (en) | Medicinal composition for treating non-alcoholic fatty liver disease | |
| CN104524171A (en) | Application of traditional Chinese medicine preparation in preparing medicine for treating hepatitis | |
| CN115487260B (en) | Traditional Chinese medicine composition for treating hypercholesterolemia or atherosclerosis and application thereof | |
| CN116832083B (en) | Preparation process and application of traditional Chinese medicine tea beverage composition capable of preventing early glycolipid metabolic disorder | |
| CN113995806B (en) | Traditional Chinese medicine composition for treating lung cancer and application thereof | |
| CN108498761B (en) | Food, health-care product or pharmaceutical composition for treating yang jaundice and preparation method and application thereof | |
| CN101693096A (en) | Medicament for treating liver cancer and preparation method thereof | |
| CN105395836A (en) | Application of traditional Chinese medicine composition to preparation of medicine for treating wind-warm lung-heat disease | |
| CN113952432A (en) | Application of three-kernel decoction in preparation of drugs for treating fatty liver |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170811 |